These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 29714661

  • 1. MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
    Zhang H, Liu W, Wang Z, Meng L, Wang Y, Yan H, Li L.
    Tumori; 2018 Jun; 104(3):221-231. PubMed ID: 29714661
    [Abstract] [Full Text] [Related]

  • 2. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D.
    PLoS One; 2013 Jun; 8(7):e68966. PubMed ID: 23935914
    [Abstract] [Full Text] [Related]

  • 3. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, Sidransky D.
    Cancer Res; 2014 Jul 15; 74(14):3995-4005. PubMed ID: 24830724
    [Abstract] [Full Text] [Related]

  • 4. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
    Song X, Wang L, Tang W, Yuan L, Liu Q, Li J, Fan D.
    Arch Pharm Res; 2023 Dec 15; 46(11-12):924-938. PubMed ID: 38032449
    [Abstract] [Full Text] [Related]

  • 5. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
    Mol Cancer Ther; 2016 Jun 15; 15(6):1387-96. PubMed ID: 26883272
    [Abstract] [Full Text] [Related]

  • 6. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, Kim HB, Kang D, Moon JY, Jung SS, Kim JO, Cho SY, Park HS, Chung C.
    Biochem Biophys Res Commun; 2017 Sep 16; 491(2):493-499. PubMed ID: 28684311
    [Abstract] [Full Text] [Related]

  • 7. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H, Okami J, Okuyama H, Nishizawa Y, Imamura F, Inoue M.
    Oncogene; 2017 May 18; 36(20):2824-2834. PubMed ID: 27893711
    [Abstract] [Full Text] [Related]

  • 8. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Siu A, Virtanen C, Jongstra J.
    Oncotarget; 2011 Dec 18; 2(12):1134-44. PubMed ID: 22193779
    [Abstract] [Full Text] [Related]

  • 9. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P, Zhang M, Nie F, Huang Z, He J, Li W, Han L.
    Biomed Pharmacother; 2017 Mar 18; 87():20-26. PubMed ID: 28040594
    [Abstract] [Full Text] [Related]

  • 10. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
    Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP.
    Neoplasia; 2015 Jan 18; 17(1):124-33. PubMed ID: 25622905
    [Abstract] [Full Text] [Related]

  • 11. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y.
    Mol Cancer Ther; 2016 Dec 18; 15(12):3040-3054. PubMed ID: 27612490
    [Abstract] [Full Text] [Related]

  • 12. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.
    Clin Cancer Res; 2009 Mar 01; 15(5):1585-92. PubMed ID: 19190133
    [Abstract] [Full Text] [Related]

  • 13. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX, Qu LY, Wen H, Zhong HS, Xu K, Qiu XS, Wang EH.
    Int J Clin Exp Pathol; 2014 Mar 01; 7(10):7304-11. PubMed ID: 25400829
    [Abstract] [Full Text] [Related]

  • 14. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW, Wang YC, Wang L, Chen CY, Lee H.
    Theranostics; 2018 Mar 01; 8(5):1256-1269. PubMed ID: 29507618
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.
    Naruo Y, Nagashima T, Ushikoshi-Nakayama R, Saeki Y, Nakakuki T, Naka T, Tanaka H, Tsai SF, Okada-Hatakeyama M.
    BMC Syst Biol; 2011 Feb 18; 5():29. PubMed ID: 21333004
    [Abstract] [Full Text] [Related]

  • 16. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M.
    Sci Rep; 2015 Nov 06; 5():16082. PubMed ID: 26542452
    [Abstract] [Full Text] [Related]

  • 17. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
    Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.
    PLoS Med; 2005 Nov 06; 2(11):e313. PubMed ID: 16187797
    [Abstract] [Full Text] [Related]

  • 18. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC.
    J Biol Chem; 2011 Jun 10; 286(23):20558-68. PubMed ID: 21487020
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
    Yang Z, Hu X, Zhang S, Zhang W, Tam KY.
    Eur J Pharmacol; 2017 Nov 15; 815():80-87. PubMed ID: 28870456
    [Abstract] [Full Text] [Related]

  • 20. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F, Zhao Y, Li X, Tang Q, Wu J, Wu W, Hann SS.
    J Ethnopharmacol; 2019 Jul 15; 239():111928. PubMed ID: 31077779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.